Who
Marshall Urist
EVP, Research & Investments
Company insider
Files Form 4 as: EVP, Research & Investments, Royalty Pharma.
In numbers
- Trades disclosed
- 60
- Buys
- 0
- Sells
- 26
- Bought
- $0
- Sold
- $25.3M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 7 May 2021
- Last trade
- 5 Oct 2026
- Last filed
- 5 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 5 Oct 2026filed 5 Oct 2026 | RPRX Royalty PharmaPharmaceuticals | SEC FORM 4 Sold | $236K4,126 at $57.10 | filing |
| 28 Sep 2026filed 30 Sep 2026 | RPRX Royalty PharmaPharmaceuticals | SEC FORM 4 Sold | $239K4,126 at $57.88 | filing |
| 28 Sep 2026filed 30 Sep 2026 | RPRX Royalty PharmaPharmaceuticals | SEC FORM 4 Sold | $239K4,126 at $57.88 | filing |
| 7 Aug 2026filed 7 Aug 2026 | RPRX Royalty Pharmaoption or derivative · Pharmaceuticals | SEC FORM 4 Code G | —3,000 at $0.00 | filing |
| 7 Aug 2026filed 7 Aug 2026 | RPRX Royalty Pharmaoption or derivative · Pharmaceuticals | SEC FORM 4 Code G | —3,000 at $0.00 | filing |
| 5 Aug 2026filed 7 Aug 2026 | RPRX Royalty PharmaPharmaceuticals | SEC FORM 4 Code A | —8,252 at $0.00 | filing |
| 5 Aug 2026filed 7 Aug 2026 | RPRX Royalty PharmaPharmaceuticals | SEC FORM 4 Code A | —8,252 at $0.00 | filing |
| 1 Jul 2026filed 2 Jul 2026 | RPRX Royalty PharmaPharmaceuticals | SEC FORM 4 Sold | $508K9,099 at $55.88 | filing |
| 1 Jul 2026filed 2 Jul 2026 | RPRX Royalty PharmaPharmaceuticals | SEC FORM 4 Sold | $508K9,099 at $55.88 | filing |
| 24 Jun 2026filed 25 Jun 2026 | RPRX Royalty PharmaPharmaceuticals | SEC FORM 4 Sold | $502K9,098 at $55.18 | filing |
| 24 Jun 2026filed 25 Jun 2026 | RPRX Royalty PharmaPharmaceuticals | SEC FORM 4 Sold | $502K9,098 at $55.18 | filing |
| 20 May 2026filed 21 May 2026 | RPRX Royalty PharmaPharmaceuticals | SEC FORM 4 Sold | $722K13,684 at $52.75 | filing |
| 20 May 2026filed 21 May 2026 | RPRX Royalty PharmaPharmaceuticals | SEC FORM 4 Sold | $722K13,684 at $52.75 | filing |
| 14 May 2026filed 15 May 2026 | RPRX Royalty PharmaPharmaceuticals | SEC FORM 4 Sold | $726K13,684 at $53.06 | filing |
| 14 May 2026filed 15 May 2026 | RPRX Royalty PharmaPharmaceuticals | SEC FORM 4 Sold | $726K13,684 at $53.06 | filing |
| 6 May 2026filed 8 May 2026 | RPRX Royalty PharmaPharmaceuticals | SEC FORM 4 Code A | —18,197 at $0.00 | filing |
| 6 May 2026filed 8 May 2026 | RPRX Royalty PharmaPharmaceuticals | SEC FORM 4 Code A | —18,197 at $0.00 | filing |
| 11 Feb 2026filed 13 Feb 2026 | RPRX Royalty PharmaPharmaceuticals | SEC FORM 4 Code A | —19,970 at $0.00 | filing |
| 11 Feb 2026filed 13 Feb 2026 | RPRX Royalty PharmaPharmaceuticals | SEC FORM 4 Code A | —19,970 at $0.00 | filing |
| 30 Jan 2026filed 2 Feb 2026 | RPRX Royalty PharmaPharmaceuticals | SEC FORM 4 Sold | $822K20,000 at $41.09 | filing |
News
Head to Head Contrast: Royalty Pharma (NASDAQ:RPRX) versus Nexentis Technologies (NASDAQ:NXTS)RPRX · dailypolitical.com · 22 Oct 2026Royalty Pharma (NASDAQ:RPRX) and Aditxt (NASDAQ:ADTX) Financial ComparisonRPRX · themarketsdaily.com · 18 Oct 2026
0 headlines in the last 90 days name Marshall Urist; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.